Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Immuneoncia Therapeutics

Request full access

Specializing in drug development and antibody engineering

Yongin-si, South KoreaFounded 2016Biotech & Life Sciences

About Immuneoncia Therapeutics

ImmuneOncia is a biopharmaceutical company specializing in immuno-oncology, which involves using the body's immune system to fight cancer. Established in 2016 as a joint venture between Yuhan (51%) and Sorrento (49%), the company focuses on developing innovative immunotherapies designed to treat various types of cancer. ImmuneOncia operates in the highly competitive biopharmaceutical market, targeting healthcare providers, research institutions, and patients in need of advanced cancer treatments. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved treatments. ImmuneOncia aims to make a significant impact on cancer treatment by offering therapies that enhance the body's natural ability to fight the disease.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
44.1/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit May 2025 $24M $24M Undisclosed ↗
OtherOther financing Dec 2021 $0 — Welcome Capital —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Immuneoncia Therapeutics website traffic

Latest recorded traffic for Immuneoncia Therapeutics is 5.1K monthly website visits, down 30.1% over the last three months. Immuneoncia Therapeutics's team grew 0% over the past year.

Latest monthly visits5.1K 3-month web change-30.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Immuneoncia Therapeutics in the Yongin-si ecosystem

Live from Dealroom

The Immuneoncia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Paratus Investment

Other known investors4 additional known investors

  • Welcome Capital
  • Dae Gyeong Investment Corporation
  • E&Investment
  • Premier Partners
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇰🇷 South Korea88.9%
🇸🇬 Singapore11.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Immuneoncia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immuneoncia Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.